Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone
Author
Standeven, Lindsay ROlson, Elizabeth
Leistikow, Nicole
Payne, Jennifer L
Osborne, Lauren M
Hantsoo, Liisa
Date
2021-04-21Journal
Current Psychiatry ReportsPublisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
Purpose of Review: To provide an overview of existing studies on alterations in gonadal and neuroactive steroids (NASs) and mood symptoms among women with polycystic ovary syndrome (PCOS). Recent Findings: Recent studies have demonstrated a previously underappreciated association between PCOS and comorbid depression and anxiety. However, most studies on affective symptoms among women with PCOS have been cross-sectional, limiting our knowledge about fluctuations in symptoms over the menstrual cycle and reproductive lifespan for women with PCOS, as well as the potential interplay between NAS alterations and mood symptoms. Changes in the NAS allopregnanolone (ALLO) have been implicated in several reproductive-related psychiatric disorders (e.g., premenstrual dysphoric disorder (PMDD) and postpartum depression (PPD)) as well as in normal reproductive functioning, warranting further investigation for its potential role in the psychiatric symptoms observed in women with PCOS. Summary: Prospective studies evaluating associations between psychiatric symptoms and NAS are needed to elucidate the biological causes of the increased rates of psychiatric symptoms among women with PCOS and inform clinical treatment. ALLO, with its role in normal reproductive function, menstrual dysregulation among women with PCOS, and reproductive-related psychiatric conditions, makes it a particularly intriguing candidate for future investigation. © 2021, The Author(s).Identifier to cite or link to this item
http://hdl.handle.net/10713/15556ae974a485f413a2113503eed53cd6c53
10.1007/s11920-021-01244-w
Scopus Count
Collections
Related articles
- Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle.
- Authors: Hantsoo L, Epperson CN
- Issue date: 2020 May
- Allopregnanolone as a mediator of affective switching in reproductive mood disorders.
- Authors: Schiller CE, Schmidt PJ, Rubinow DR
- Issue date: 2014 Sep
- Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.
- Authors: Bixo M, Johansson M, Timby E, Michalski L, Bäckström T
- Issue date: 2018 Feb
- Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome.
- Authors: Jedel E, Gustafson D, Waern M, Sverrisdottir YB, Landén M, Janson PO, Labrie F, Ohlsson C, Stener-Victorin E
- Issue date: 2011 Nov
- Psychiatric comorbidities and adverse childhood experiences in women with self-reported polycystic ovary syndrome: An Australian population-based study.
- Authors: Tay CT, Teede HJ, Loxton D, Kulkarni J, Joham AE
- Issue date: 2020 Jun